List of potential top 10 FDA approved drugs for repurposing against non-structural SARS-CoV2 targets along with their known therapeutic indication.

Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV‑2

Biering, Scott B
Van Dis, Erik
Wehri, Eddie
Yamashiro, Livia H
Nguyenla, Xammy
Dugast-Darzacq, Claire
Graham, Thomas GW
Stroumza, Julien R
Golovkine, Guillaume R
Roberts, Allison W
Fines, Daniel M
Spradlin, Jessica N
Ward, Carl C
Bajaj, Teena
Dovala, Dustin
Schulze-Gamen, Ursula
Bajaj, Ruchika
Fox, Douglas M
Ott, Melanie
Murthy, Niren
Nomura, Daniel K
Schaletzky, Julia
Stanley, Sarah A

August 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus dis...

Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets

Pei-Chen Yu
Chen-Hao Huang
Chih-Jung Kuo
Po-Huang Liang
Lily Hui-Ching Wang
Max Yu-Chen Pan
Sui-Yuan Chang
Tai-Ling Chao
Si-Man Ieong
Jun-Tung Fang
Hsuan-Cheng Huang
Hsueh-Fen Juan

January 2022

Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been rapidly spreading ...

Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2

Biering, Scott B.
Van Dis, Erik
Yamashiro, Livia H.
Nguyenla, Xammy
Wehri, Eddie
Dugast-Darzacq, Claire
Graham, Thomas G.W.
Stroumza, Julian
Golovkine, Guillaume
Roberts, Allison W.
Fines, Daniel M.
Fox, Douglas M.
Ward, Carl
Spradlin, Jessica
Dovala, Dustin
Schaletzky, Julia
Stanley, Sarah A.

June 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus dis...

List of potential top 10 FDA approved drugs for repurposing against structural SARS-CoV2 targets along with their known therapeutic indication.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

List of potential top 10 FDA approved drugs for repurposing against structural SARS-CoV2 targets alo...

List of potential top 10 FDA approved drugs for repurposing against accessory SARS-CoV2 targets along with their known therapeutic indication.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

List of potential top 10 FDA approved drugs for repurposing against accessory SARS-CoV2 targets alon...

List of FDA approved drugs interacting with more than three SARS-CoV2 targets along with their original indications.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

List of FDA approved drugs interacting with more than three SARS-CoV2 targets along with their origi...

The binding score distribution of top 10 FDA approved drugs against SARS-CoV2 proteins.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

The figure depicts the distribution of top the 10 FDA approved drugs against SARS-CoV2 proteins name...

Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity

Van Damme, Ellen

May 2021

This report describes the most relevant results of screening a drug repurposing library consisting o...

Scaffold analysis of top scored drugs across 24 SARS-CoV2 targets.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

The level 2 and level 3 common scaffolds that are present among the top scored drug molecules across...

S1 File -

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

Drug repurposing has emerged as an important strategy and it has a great potential in identifying th...

Schematic workflow of screening known drugs for therapeutic indications against SARS-CoV2 selected targets.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

Schematic workflow of screening known drugs for therapeutic indications against SARS-CoV2 selected t...

Discovery of new drug indications for COVID-19: A drug repurposing approach.

Priyanka Kumari
Bikram Pradhan
Maria Koromina
George P Patrinos
Kristel Van Steen

January 2022

MotivationThe outbreak of coronavirus health issues caused by COVID-19(SARS-CoV-2) creates a global ...

Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

Christopher A. MacRaild
Muzaffar-Ur-Rehman Mohammed
Faheem
Sankaranarayanan Murugesan
Ian K. Styles
Amanda L. Peterson
Carl M. J. Kirkpatrick
Matthew A. Cooper
Enzo A. Palombo
Moana M. Simpson
Hardik A. Jain
Vinti Agarwal
Alexander J. McAuley
Anupama Kumar
Darren J. Creek
Natalie L. Trevaskis
Seshadri S. Vasan

October 2022

SARS-CoV-2 is the cause of the COVID-19 pandemic which has claimed more than 6.5 million lives world...

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Touret, Franck
Gilles, Magali
Barral, Karine
Nougairède, Antoine
van Helden, Jacques
Decroly, Etienne
de Lamballerie, Xavier
Coutard, Bruno

August 2020

International audienceA novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly sp...

Drug Repurposing of Potential Inhibitors to Two Proteases of the Novel Coronavirus

Li, Joyce, \u2722
Smith, Aidan, \u2722

April 2021

As the SARS-CoV-2 global pandemic rages on with new variants on the rise, rapid and effective therap...

Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV‑2

Biering, Scott B
Van Dis, Erik
Wehri, Eddie
Yamashiro, Livia H
Nguyenla, Xammy
Dugast-Darzacq, Claire
Graham, Thomas GW
Stroumza, Julien R
Golovkine, Guillaume R
Roberts, Allison W
Fines, Daniel M
Spradlin, Jessica N
Ward, Carl C
Bajaj, Teena
Dovala, Dustin
Schulze-Gamen, Ursula
Bajaj, Ruchika
Fox, Douglas M
Ott, Melanie
Murthy, Niren
Nomura, Daniel K
Schaletzky, Julia
Stanley, Sarah A

August 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus dis...

Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets

Pei-Chen Yu
Chen-Hao Huang
Chih-Jung Kuo
Po-Huang Liang
Lily Hui-Ching Wang
Max Yu-Chen Pan
Sui-Yuan Chang
Tai-Ling Chao
Si-Man Ieong
Jun-Tung Fang
Hsuan-Cheng Huang
Hsueh-Fen Juan

January 2022

Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been rapidly spreading ...

Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2

Biering, Scott B.
Van Dis, Erik
Yamashiro, Livia H.
Nguyenla, Xammy
Wehri, Eddie
Dugast-Darzacq, Claire
Graham, Thomas G.W.
Stroumza, Julian
Golovkine, Guillaume
Roberts, Allison W.
Fines, Daniel M.
Fox, Douglas M.
Ward, Carl
Spradlin, Jessica
Dovala, Dustin
Schaletzky, Julia
Stanley, Sarah A.

June 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus dis...

List of potential top 10 FDA approved drugs for repurposing against structural SARS-CoV2 targets along with their known therapeutic indication.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

List of potential top 10 FDA approved drugs for repurposing against structural SARS-CoV2 targets alo...

List of potential top 10 FDA approved drugs for repurposing against accessory SARS-CoV2 targets along with their known therapeutic indication.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

List of potential top 10 FDA approved drugs for repurposing against accessory SARS-CoV2 targets alon...

List of FDA approved drugs interacting with more than three SARS-CoV2 targets along with their original indications.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

List of FDA approved drugs interacting with more than three SARS-CoV2 targets along with their origi...

The binding score distribution of top 10 FDA approved drugs against SARS-CoV2 proteins.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

The figure depicts the distribution of top the 10 FDA approved drugs against SARS-CoV2 proteins name...

Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity

Van Damme, Ellen

May 2021

This report describes the most relevant results of screening a drug repurposing library consisting o...

Scaffold analysis of top scored drugs across 24 SARS-CoV2 targets.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

The level 2 and level 3 common scaffolds that are present among the top scored drug molecules across...

S1 File -

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

Drug repurposing has emerged as an important strategy and it has a great potential in identifying th...

Schematic workflow of screening known drugs for therapeutic indications against SARS-CoV2 selected targets.

Esther Jamir (16806806)
Himakshi Sarma (6056102)
Lipsa Priyadarsinee (14604302)
Kikrusenuo Kiewhuo (14604299)
Selvaraman Nagamani (819665)
G. Narahari Sastry (472961)

August 2023

Schematic workflow of screening known drugs for therapeutic indications against SARS-CoV2 selected t...

Discovery of new drug indications for COVID-19: A drug repurposing approach.

Priyanka Kumari
Bikram Pradhan
Maria Koromina
George P Patrinos
Kristel Van Steen

January 2022

MotivationThe outbreak of coronavirus health issues caused by COVID-19(SARS-CoV-2) creates a global ...

Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

Christopher A. MacRaild
Muzaffar-Ur-Rehman Mohammed
Faheem
Sankaranarayanan Murugesan
Ian K. Styles
Amanda L. Peterson
Carl M. J. Kirkpatrick
Matthew A. Cooper
Enzo A. Palombo
Moana M. Simpson
Hardik A. Jain
Vinti Agarwal
Alexander J. McAuley
Anupama Kumar
Darren J. Creek
Natalie L. Trevaskis
Seshadri S. Vasan

October 2022

SARS-CoV-2 is the cause of the COVID-19 pandemic which has claimed more than 6.5 million lives world...

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Touret, Franck
Gilles, Magali
Barral, Karine
Nougairède, Antoine
van Helden, Jacques
Decroly, Etienne
de Lamballerie, Xavier
Coutard, Bruno

August 2020

International audienceA novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly sp...

Drug Repurposing of Potential Inhibitors to Two Proteases of the Novel Coronavirus

Li, Joyce, \u2722
Smith, Aidan, \u2722

April 2021

As the SARS-CoV-2 global pandemic rages on with new variants on the rise, rapid and effective therap...

Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV‑2

Biering, Scott B
Van Dis, Erik
Wehri, Eddie
Yamashiro, Livia H
Nguyenla, Xammy
Dugast-Darzacq, Claire
Graham, Thomas GW
Stroumza, Julien R
Golovkine, Guillaume R
Roberts, Allison W
Fines, Daniel M
Spradlin, Jessica N
Ward, Carl C
Bajaj, Teena
Dovala, Dustin
Schulze-Gamen, Ursula
Bajaj, Ruchika
Fox, Douglas M
Ott, Melanie
Murthy, Niren
Nomura, Daniel K
Schaletzky, Julia
Stanley, Sarah A

August 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus dis...

Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets

Pei-Chen Yu
Chen-Hao Huang
Chih-Jung Kuo
Po-Huang Liang
Lily Hui-Ching Wang
Max Yu-Chen Pan
Sui-Yuan Chang
Tai-Ling Chao
Si-Man Ieong
Jun-Tung Fang
Hsuan-Cheng Huang
Hsueh-Fen Juan

January 2022

Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been rapidly spreading ...

Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2

Biering, Scott B.
Van Dis, Erik
Yamashiro, Livia H.
Nguyenla, Xammy
Wehri, Eddie
Dugast-Darzacq, Claire
Graham, Thomas G.W.
Stroumza, Julian
Golovkine, Guillaume
Roberts, Allison W.
Fines, Daniel M.
Fox, Douglas M.
Ward, Carl
Spradlin, Jessica
Dovala, Dustin
Schaletzky, Julia
Stanley, Sarah A.

June 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus dis...

List of potential top 10 FDA approved drugs for repurposing against non-structural SARS-CoV2 targets along with their known therapeutic indication.

Abstract

Extracted data

List of potential top 10 FDA approved drugs for repurposing against non-structural SARS-CoV2 targets along with their known therapeutic indication.

Abstract

Extracted data

Related items

Related items